Shanghai Fosun To Buy Gland Pharma


The Foreign Investment Promotion Board has cleared Shanghai Fosun's deal to acquire Small Volume Parenterals (SVPs) manufacturer, Gland Pharma, on March 30, 2017. The FIPB approved 10 FDI proposals, which also include Gland Pharma’s proposal, worth Rs 4300 crore.

In the previous week, Gland Pharma-Shanghai Fosun deal was postponed by the inter-ministerial body which is worth 1.4 billion. Now the deal has been approved, and the capital infusion will help Gland Pharma establish its presence in Africa, Europe & Japan.

Gland Pharma develops & manufactures generic injectables, primarily for the US market. Established in 1978, the company sells its products in India and other semi-regulated markets. This is the 1st deal in the pharma sector after government allowed 74% FDI through the automatic route.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: